Trillium Therapeutics Inc (NASDAQ:TRIL) target price raised to $18.00, reported today by Ladenburg Thalmann
- Updated: September 18, 2016
In a report released on 8/03/2016 Ladenburg Thalmann bumped up the target price of Trillium Therapeutics Inc (NASDAQ:TRIL) from $0 to $18 reporting a possible upside of 0.95%.
Boasting a price of $9.21, Trillium Therapeutics Inc (NASDAQ:TRIL) traded 0.68% higher on the day. The last stock close is down 30.76% from the two hundred day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trillium Therapeutics Inc has recorded a 50-day moving average of $11.68 and 200-day moving average of $10.16. 39,568 shares of Trillium Therapeutics Inc traded hands, down from ann avg. trading volume of 70,334
Recent Performance Graph:
Trillium Therapeutics Inc has a one-year low of $6.62 and a 52 week high of $19.08. TRIL’s total market value is currently $0.0.
More About Trillium Therapeutics Inc (NASDAQ:TRIL)
Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, and Canada.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.